Cargando…

Laboratory Assessment of Unfractionated Heparin (UFH) with Activated Clotting Time (ACT) and Anti-Xa Activity during Peripheral Arterial Angiographic Procedure

Activated clotting time (ACT) is used in cardiac surgery for monitoring unfractionated heparin (UFH). In endovascular radiology, ACT use is less established. We aimed to test the validity of ACT in UFH monitoring in endovascular radiology. We recruited 15 patients undergoing endovascular radiologic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Helin, Tuukka, Tirri, Tomi, Korkala, Heidi, Lappalainen, Kimmo, Joutsi-Korhonen, Lotta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137659/ https://www.ncbi.nlm.nih.gov/pubmed/37189590 http://dx.doi.org/10.3390/diagnostics13081489

Ejemplares similares

Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study()
por: DeNucci, Gilberto, et al.
Publicado: (2023)

Pregnancy outcome in women with mechanical prosthetic heart valvesat their first trimester of pregnancy treated with unfractionated heparin (UFH) or enoxaparin: A randomized clinical trial
por: Movahedi, Minoo, et al.
Publicado: (2020)

Comparison of novel thrombin generation methods with established techniques is mandatory
por: Helin, Tuukka, et al.
Publicado: (2021)

Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy
por: McLaughlin, Kevin, et al.
Publicado: (2019)

Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy
por: Byun, Jung-Hyun, et al.
Publicado: (2016)

Anticoagulated patients exhibit intact endogenous thrombin potential using ST Genesia unlike the Calibrated Automated Thrombogram
por: Helin, Tuukka A., et al.
Publicado: (2021)

Novel Ex Vivo DOAC Removal Methods Reduce Interference in Lupus Anticoagulant Testing
por: Savola, Paula, et al.
Publicado: (2022)

Use of activated clotting time to monitor anticoagulation in patients receiving unfractionated heparin on renal replacement therapy
por: Bidwai, A, et al.
Publicado: (2011)

Monitoring Unfractionated Heparin in Adult Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): ACT, APTT, or ANTI-XA?
por: Nguyen, Tung Phi, et al.
Publicado: (2021)

Evaluation of anti-Xa levels in patients with venous thromboembolism within the first 48 h of anticoagulation with unfractionated heparin
por: Nguyen, Lily, et al.
Publicado: (2023)

Anaemia and enhancement of coagulation are associated with severe COVID-19 infection
por: Helin, Tuukka A., et al.
Publicado: (2021)

Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy
por: Zeljkovic, Ivan, et al.
Publicado: (2021)

Unfractionated and low molecular weight heparin
por: Lima, Marcelo, et al.
Publicado: (2014)

Unfractionated Heparin Promotes Osteoclast Formation in Vitro by Inhibiting Osteoprotegerin Activity
por: Li, Binghan, et al.
Publicado: (2016)

Unfractionated heparin and mechanical thromboprophylaxis in hip arthroplasty
por: Garcia, Flávio Luís, et al.
Publicado: (2015)

Cartridge-Based Thromboelastography Can Be Used to Monitor and Quantify the Activity of Unfractionated and Low-Molecular-Weight Heparins
por: Dias, João D., et al.
Publicado: (2019)

Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments
por: Davenport, Andrew
Publicado: (2012)

Impact of COVID-19 on monitoring of therapeutic unfractionated heparin
por: Adie, Sarah K., et al.
Publicado: (2020)

Quantitative Analysis of Impurities in Unfractionated Heparin of Bovine Origin
por: Workman, Wesley E., et al.
Publicado: (2020)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Resistance to unfractionated heparin in the ICU: evaluation and management options
por: Levy, Jerrold H., et al.
Publicado: (2023)

Unfractionated heparin in acute chest syndrome: a pilot feasibility randomized controlled trial of unfractionated heparin vs. standard of care in acute chest syndrome
por: Seaman, Craig D., et al.
Publicado: (2020)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Opposition: Unfractionated heparin should no longer be used in the catheterization laboratory
por: Kim, Moo Hyun, et al.
Publicado: (2014)

Low-Molecular-Weight Heparin and Unfractionated Heparin Decrease Th-1, 2, and 17 Expressions
por: Huang, Jing-Ning, et al.
Publicado: (2014)

Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin
por: Maharaj, Satish, et al.
Publicado: (2018)

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)

Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement
por: Lardinois, Benjamin, et al.
Publicado: (2022)

Distinct Effects of Unfractionated Heparin versus Bivalirudin on Circulating Angiogenic Peptides
por: Kapur, Navin K., et al.
Publicado: (2012)

Nonclinical Evaluation of Novel Cationically Modified Polysaccharide Antidotes for Unfractionated Heparin
por: Kalaska, Bartlomiej, et al.
Publicado: (2015)

Individual variation in unfractionated heparin dosing after pediatric cardiac surgery
por: Hikino, Keiko, et al.
Publicado: (2020)

Validation of high concentrated thrombin time assay for unfractionated heparin monitoring
por: Apipongrat, Dollapak, et al.
Publicado: (2022)

Predicting Therapeutic Response to Unfractionated Heparin Therapy: Machine Learning Approach
por: Abdel-Hafez, Ahmad, et al.
Publicado: (2022)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
por: Amin, Alpesh, et al.
Publicado: (2023)

The missing slope: paradoxical shortening of activated partial thromboplastin time in a patient on unfractionated heparin therapy
por: Lapić, Ivana, et al.
Publicado: (2021)

Characterization of a Bioflocculant (MBF-UFH) Produced by Bacillus sp. AEMREG7
por: Okaiyeto, Kunle, et al.
Publicado: (2015)

The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
por: Afshari, Daryoush, et al.
Publicado: (2015)

An Antithrombin-Heparin Complex Increases the Anticoagulant Activity of Fibrin Clots
por: Smith, Lesley J., et al.
Publicado: (2008)

Elucidating the specificity of non-heparin-based conformational activators of antithrombin for factor Xa inhibition
por: Rashid, Qudsia, et al.
Publicado: (2014)

A comparative study of dalteparin and unfractionated heparin in patients with unstable angina pectoris
por: Amane, Hanmant S., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_iam8k2i97aapp1gh154911bf1l